MaravirocA Review of its Use in the Management of CCR5-Tropic HIV-1 Infection

被引：0
作者：
Caroline M. Perry
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs | 2010年 / 70卷
关键词：
Efavirenz; Darunavir; Raltegravir; Maraviroc; Enfuvirtide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Maraviroc (Celsentri®; Selzentry®) is a CCR5 coreceptor antagonist used in the treatment of CCR5-tropic HIV-1 infection. Administered orally twice daily, maraviroc, in combination with optimized background therapy regimens, showed good virological and immunological efficacy over 48 weeks in antiretroviral treatment-experienced patients aged ≥16 years with CCR5-tropic HIV-1 infection, in the randomized, double-blind, placebo-controlled, multicentre, MOTIVATE 1 and MOTIVATE 2 studies. Initial data indicate that the efficacy of maraviroc in this patient population is sustained for up to 96 weeks.
引用
收藏
页码：1189 / 1213
页数：24
相关论文
共 99 条
[1]  
Hammer SM(2008)Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society USA panel JAMA 300 555-70
[2]  
Eron JJ(2008)British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 HIV Med 9 563-608
[3]  
Reiss P(2008)Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection AIDS Patient Care STDS 22 459-71
[4]  
Gazzard BG(2009)Novel targets for antiretroviral therapy: clinical progress to date Drugs 69 31-50
[5]  
Anderson J(2008)A review of the clinical pharmacology of maraviroc: introduction Br J Clin Pharmacol 65 1-4
[6]  
Babiker A(2008)Reviews of anti-infective agents Maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 47 236-41
[7]  
Moyle G(2006)Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists J Med Chem 49 2851-7
[8]  
Gatell J(2007)Genotypic coreceptor analysis Eur J Med Res 12 453-62
[9]  
Perno CF(2008)Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists Mol Pharmacol 73 789-800
[10]  
Dau B(2006)Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir J Virol 80 4909-20
12345678910